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Abstract
In multiple myeloma, circulating ‘‘clonotypic’’ B cells, that express the immunoglobulin rearrangement of the malignant
plasma cell clone, can be indirectly detected by PCR. Their role as potential ‘‘feeder’’ cells for the malignant plasma cell pool
remains controversial. Here we established for the first time an approach that allows direct tracking of such clonotypic cells
by labeling with patient-specific immunoglobulin ligands in 15 patients with myeloma. Fifty percent of patients showed
evidence of clonotypic B cells in blood or bone marrow by PCR. Epitope-mimicking peptides from random libraries were
selected on each patient’s individual immunoglobulin and used as ligands to trace cells expressing the idiotypic
immunoglobulin on their surface. We established a flow cytometry and immunofluorescence protocol to track clonotypic B
cells and validated it in two independent monoclonal B cell systems. Using this method, we found clonotypic B cells in only
one out of 15 myeloma patients. In view of the assay’s validated sensitivity level of 1023, this surprising data suggests that
the abundance of such cells has been vastly overestimated in the past and that they apparently represent a very rare
population in myeloma. Our novel tracing approach may open perspectives to isolate and analyze clonotypic B cells and
determine their role in myeloma pathobiology.
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Introduction
Multiple myeloma is the second most common hematological
malignancy worldwide [1,2]. The disease is characterized by a
monoclonal expansion of malignant plasma cells (PC) in the bone
marrow, committed to the production of a patient-specific
monoclonal serum immunoglobulin, the ‘‘paraprotein’’. While
many patients initially respond well to PC-directed therapies,
almost all patients relapse and ultimately succumb to the disease
[3]. Although the malignant PC clone is held responsible for most
myeloma-related morbidity such as anemia, renal failure and bone
lesions, it has been a subject of debate whether or not these cells
possess enough proliferative potential to sustain the disease. The
discovery of (surface) immunoglobulin-positive B cells expressing
the same patient-individual variable region immunoglobulin (Ig)
rearrangement as the malignant PC clone – so called clonotypic B
cells – has therefore fueled speculations about a potential (pre-)
malignant B cell compartment with stem cell like properties
feeding the malignant PC compartment in multiple myeloma
[4,5,6,7,8]. Attempts have been made to use anti-idiotypic
antibodies in the detection of B cell populations with clonotypic
surface Ig, but their specificity has been limited, since they react
with more than one myeloma Ig and also recognize a number of
normal B cell clones [9,10]. Molecular detection of potential
myeloma precursor B cells has therefore been mainly based on
PCR amplification of the patient-specific Ig rearrangement from
either peripheral blood or bone marrow-derived DNA or cDNA
(mRNA) [11,12,13,14,15,16,17]. To discriminate between con-
taminating IgG- or IgA-positive PCs and clonotypic B cells, many
studies worked on the purified CD19-positive B cell fraction and/
or used IgM-specific primers for immunoglobulin gene amplifica-
tion (although some studies looked at other isotypes as well). The
percentage of patients in which myeloma-related Ig-positive
clonotypic B cells could be detected ranged between 40% and
87% [15,17,18]. Limiting dilution PCRs indicated that in
myeloma patients between 0.24% and 25% of peripheral blood
mononuclear cells (PBMC) and up to 66% of all peripheral B cells
represent clonotypic B cells [15,16,17]. This data implies that a
substantial proportion of B cells are clonally related to the
malignant PC clone. However, a rather high interpatient and
interstudy variability (with some studies suggesting lower percent-
ages of clonotypic B cells [18,19,20]), possibly related to
methodical heterogeneity of the PCR technique, as well as
potential confounders (unspecific primer annealing or expression
of atypical, non-clinical Ig transcripts by myeloma subclones [21])
may limit the validity of such PCR-based approaches. When
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looking at different stages of the disease, the estimated frequencies
of such clonotypic cells varied between lower levels after chemo-
therapy and higher levels in relapsed disease [14,15,16,
22,23,24,25]. This data has been interpreted as preliminary
evidence that these cells do not merely represent non-malignant
clonotypic remnant B cells which had initially produced the
malignant plasma cell clone, but supports their role as an active
‘‘feeder’’ in myelomagenesis and myeloma progression. To directly
and functionally address the biological significance of this B cell
population, peripheral B cells from myeloma patients have been
xenotransplanted into immunodeficient mice. These studies
produced inconsistent findings [26,27,28,29] [30,31]. Importantly,
if the hypothesis of an active B cell ‘‘feeder’’ population holds true,
one would expect these B cells to mirror many genetic changes
observed in the malignant PC compartment. Towards this end,
several studies have compared the genetic lesions in PCs with those
in the peripheral B cell compartment, supporting a model of
intraclonal evolution at the PC level [32,33,34,35,36,37,38]. More
evidence questioning the role of clonotypic B cells as ‘‘feeders’’ of
the malignant PC compartment came from a recent study on the
clonal hierarchy in light-chain myeloma [38] and from the analysis
of class switch recombination from IgM to IgG or IgA in multiple
myeloma [39].
Taken together, the concept of (pre-)malignant surface Ig-
positive clonotypic B cells feeding the malignant PC compartment
in a stem cell like manner is still highly controversial. One of the
major problems hampering scientific progress can be ascribed to
the fact that clonotypic B cells have been only detectable by PCR
so far. Besides general concerns regarding this approach as
indicated above, a major drawback of PCR-based methods is that
the cells of interest cannot be morphologically identified or even
directly isolated for further analyses to determine their biological
role.
To overcome this critical challenge irrespective of the
controversy on the functional relevance of conotypic cells in
myeloma, we set out to develop a tool to specifically detect and
isolate these cells for exact quantification and to obtain the
possibility of their further functional characterization in future
studies. Therefore, we established patient-individual ligands
mimicking the epitope recognized by the myeloma immuno-
globulin to specifically target clonotypic surface Ig-positive B
cells from myeloma patients.. Our analysis of 15 myeloma
patients indicates, that clonotypic B cells are a very rare event in
myeloma and that their absolute numbers and relative
frequencies have been significantly overestimated by indirect
PCR-based quantification. This study, as a matter of fact, does
not provide evidence to reject the ‘‘feeder’’ B cell hypothesis.
However, the limited percentage of patients with PCR-
detectable and ligand-detectable clonotypic B cells challenges
the concept of an active pre-switch B cell ‘‘feeder’’ compartment
as a general principle and indispensable prerequisite for myelo-
ma pathogenesis and progression.
Table 1. Clinical characteristics of myeloma patients.*
Patient Code Diagnosis
Date of clinical
sample acquisition Treatment
Remission status (at
date of sample
acquisition)
MM001 06/2003 06/2003 and 07/2008 autologous stem cell transplant (11/2004), idiotype vaccination (06-11/2005),
lenalidomide maintenance (06/2006-02/2007), lenalidomide/dexamethasone
(03/2008-07/2008)
PR/SD
MM003 02/2002 02/2002 autologous stem cell transplant (05/2003), thalidomide maintenance,
bortezomib (02-04/2005), idiotype vaccination (06-11/2005),
cyclophosphamide/bortezomib/dexamethasone (02-07/2006)
active disease
MM008 03/2005 03/2005 autologous stem cell transplant (11/2005), allogeneic stem cell
transplant (02/2006)
active disease
MM020 05/2005 05/2005 and 09/2008 autologous stem cell transplant (11/2005), idiotype vaccination
(08/2006-09/2008)
PR
MM021 09/2000 05/2009 autologous stem cell transplant (11/2001 and 07/2007), lenalidomide/
dexamethasone (07-12/2008), bortezomib/dexamethasone (05/2009)
PD
MM022 05/2004 05/2009 autologous stem cell transplant (12/2005), bortezomib/dexamethasone
(12/2006-08/2007), lenalidomide/dexamethasone (01-09/2008),
thalidomide/bortezomib/dexamethasone (10/2008-02/2009), allogeneic
stem cell transplant (02/2009)
PD
MM023 12/2008 03/2009 bortezomib/dexamethasone (01-03/2009) PR
MM025 09/2005 08/2009 autologous stem cell transplant (11/2005 and 01/2006),
bortezomib/dexamethasone (07-08/2009)
PD
MM026 08/2009 08/2009 - active disease
MM031 11/2007 04/2010 bortezomib/dexamethasone (12/2007-01/2008), autologous stem cell
transplant (05/2008 and 08/2008), bortezomib maintenance
PD
MM032 01/2011 01/2011 autologous stem cell transplant (06/2011 and 09/2011) active disease
MM034 02/2011 02/2011 - active disease
MM036 2007 02/2011 bortezomib (01/2011) PR
MM048 03/2011 03/2011 autologous stem cell transplant (09/2011) active disease
MM050 01/2003 04/2011 intermittent lenalidomide (01/2003-04/2011), bortezomib/dexamethasone
(04-08/2011)
PD
*MM=multiple myeloma, PR = partial remission, SD= stable disease, PD=progressive disease.
doi:10.1371/journal.pone.0031998.t001
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Materials and Methods
Ethics statement
Blood samples of myeloma patients visiting the Freiburg and
Hamburg Medical Centers’ outpatient units were obtained after
informed written consent. This study was specifically approved by
the institutional review board of the University of Freiburg and the
Physician’s Association in Hamburg. Control cells were obtained
from healthy donors (HD). Residual bone marrow obtained for
routine clinical testing was banked after completion of diagnostic
procedures and used for this study after informed consent.
Patients’ characteristics
A total of 15 myeloma patients were included in this study.
Table 1 summarizes the clinical characteristics, including first
diagnosis, treatment and remission status at the time of sample
collection.
Preparation of clinical samples and immunoglobulin
purification
Peripheral blood mononuclear cells (PBMC) were isolated from
the blood of myeloma patients by Ficoll density gradient centrifuga-
tion (Biacoll, Biochrom AG, Berlin, Germany). Viable PBMCs were
resuspended in 90% fetal calf serum (FCS) and 10% dimethyl
sulfoxide (DMSO) and stored in liquid nitrogen until use for
subsequent FACS analysis, RNA preparation (Roboklon Kit,
Roboklon, Berlin, Germany) and cDNA generation (Omniscript(R)
RT Kit by Qiagen, Hilden, Germany). The remaining serum was
used for Ig purification by protein-A sepharose (GE Healthcare,
Buckinghamshire, UK) for IgG paraproteins and Jacalin (Pierce,
Rockford, Illinois) for IgA paraproteins as described by the supplier.
Bone marrow samples collected from myeloma patients were treated
with a lysis buffer (155 mM ammonium chloride, 10 mM potassium
hydrogen carbonate and 1 mM ethylenediaminetetraacetic acid) to
eliminate erythrocytes. The bone marrow mononuclear cells
(BMMNCs) were resuspended in 90% FCS and 10% DMSO,
stored in liquid nitrogen and used for the same applications as
described for PBMCs. The Burkitt’s lymphoma cell line CA46
(ATCC#CRL-1648TM) and PBMCs from a CLL patient (CLL024),
isolated by Ficoll density gradient centrifugation and containing more
than 90% monoclonal B cells, were included as controls.
Sequencing of immunoglobulin variable regions of
malignant plasma cell clones
To amplify Ig variable heavy and light chain genes from bone
marrow, cDNA of myeloma patients, polymerase chain reactions
(PCR) were performed with family-specific degenerated leader
primers and the corresponding reverse primer either designed for
the kappa or lambda light chain constant region or for the IgG or
IgA heavy chain constant region (Table S1). PCR products of
correct size were excised from agarose gels, purified (HiYield(R)
PCR Clean-up/Gel Extraction Kit by SLG, Gauting, Germany)
and subcloned into pJet1.2 cloning vector (Fermentas, St. Leon-
Rot, Germany) according to the manufacturer’s instructions. A
minimum of eight clones were sequenced per variable region
(Seqlab, Go¨ttingen, Germany).
Detection of IgM-positive clonotypic B cells by semi-
nested PCR
For detection of IgM-positive clonotypic B cells from
peripheral blood and bone marrow, a semi-nested PCR approach
was established as illustrated in Figure 1A. Therefore, unless
indicated otherwise, patient-specific heavy chain complementar-
ity determining region 3 (HCDR3) forward primers were
designed (Table S1). As a positive control and in order to test
the individual HCDR3 primers, the PC’s Ig rearrangement was
amplified by semi-nested PCR from BMMNC cDNA (1st PCR:
family-specific forward primer + IgG (or IgA, respectively) reverse
primer, 2nd PCR: HCDR3 forward primer+IgG (or IgA,
respectively) reverse primer; Figure 1A, upper panel, and
Figure 1B, left panels). To detect IgM-positive clonotypic B cells
from PBMC- or BMMNC-derived cDNA, the IgG/IgA reverse
primer was replaced by an IgM reverse primer (Figure 1A, lower
panel, and Figure 1B middle and right panels). PCR products
were electrophoresed in agarose gels and visualized by ethidium
bromide staining.
Recombinant expression of myeloma Ig
cDNAs from primary myeloma cells of patients MM001,
MM003, MM008 and MM020 were prepared and Fab fragments
containing the variable heavy and light chain regions of the
respective myeloma Ig were produced commercially (CellGenix,
Freiburg, Germany) as described previously [40,41]. Fab frag-
ments were purified by His-tag affinity chromatography. The Ig of
myeloma patient MM021, CLL patient 024 and of the Burkitt’s
lymphoma cell line CA46 was cloned into the plasmid pBUD,
expressed as IgG1 antibody in HEK293T cells and purified by
protein-A affinity chromatography [42].
Random phage display peptide libraries
Four random phage display peptide libraries were used: three linear
(X7, X12, X18) and one beta-sheet conformation (X4CX6CX4)
(C=cysteine; X= random amino acid). The X12 library was
purchased from New England Biolabs (Frankfurt, Germany) and
processed as recommended by the manufacturer. All other libraries
were generated as described previously [43,44,45,46,47,48,49].
Phage library selection
The libraries were screened on recombinantly expressed
myeloma Ig or purified paraprotein as previously described
[50,51] after a two-fold negative selection on polyclonal human
Ig (Octapharma, Lachen, Switzerland). Random clones from the
third or fourth panning round were sequenced (Seqlab, Go¨ttin-
gen, Germany).
Single clone phage binding
Phage clones (108 transducing units [TU]) were incubated on
myeloma Ig (Fab or purified paraprotein) and control Ig. Bound
Figure 1. Detection of clonotypic Ig rearrangements by semi-nested PCR. A: Illustration of semi-nested PCR approach for the detection of
clonotypic Ig rearrangements. Ig genes were amplified using VH family-specific forward leader primers and constant region specific reverse primers
(1st PCR). A secondary PCR was used to specifically amplify the clonotypic Ig rearrangement with a patient-individual HCDR3-specific primer.
PC = plasma cell, Ig = immunoglobulin, VH=heavy chain variable region, CH=heavy chain constant region, HCDR3=heavy chain complementarity
determining region 3. B: Detection of clonotypic Ig-rearrangements in myeloma PBMCs and BMMNCs of patients MM021, MM025 and MM036. Semi-
nested PCRs were performed as described in A. PCR products were loaded on agarose gels stained with ethidium bromide. MM=Multiple Myeloma,
PBMC=peripheral blood mononuclear cell, BMMNC=bone marrow mononuclear cell.
doi:10.1371/journal.pone.0031998.g001
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phage were either quantified by ELISA as suggested by the NEB
phage display manual or – more accurately - based on E. coli
K91kan or ER2738 (for X12 phage) bacterial infection [43,50,51].
Either insertless fd tet or a phage displaying the random insert
YMTPPLSSQQKS (from X12 library) were used as control phage
for all experiments.
GST-fusion protein and competition assays
The oligonucleotide encoding the phage-derived peptide
FLNGCDKEDWMCWVTT was digested with BamHI and
EcoRI, and cloned into pGEX-2TK (Amersham, Buckingham-
shire, UK). Proteins were expressed in E. coli BL21 (Invitrogen,
Camarillo, California) and purified according to the manufactur-
er’s instructions. Competition experiments were done with GST-
fusion proteins as described [50].
Detection of surface Ig-positive clonotypic B cells by
immunofluorescence using patient-individual ligands
Myeloma patients’ PBMCs, the Burkitt’s lymphoma cell line
CA46 (ATCC #CRL-1648TM), primary CLL cells (CLL024) and
a variety of control cells (healthy donor and CLL PBMCs as well
as the Burkitt’s lymphoma cell line DG-75 [ATCC #CRL-
2625TM]) were incubated for 10 min with a 100-fold excess of the
respective selected phage, washed with PBS, sedimented on
adhesion slides (Marienfeld, Lauda-Ko¨nigshofen, Germany), fixed
with 2% paraformaldehyde and blocked with 3% BSA. Insertless
fd tet and random insert phage YMTPPLSSQQKS were used as
controls. Bound phage were stained with a polyclonal anti-fd
bacteriophage biotin-conjugated antibody (Sigma, Saint Louis,
Missouri) followed by fluorescent labeling with streptavidin-
fluoresceinisothiocyanate (streptavidin-FITC, Invitrogen, Camar-
illo, California). Nuclei were counterstained with DAPI-containing
mounting medium (VectaShield, Vector Laboratories, Burlin-
game, California). Images were obtained by confocal microscopy
(Leika TCS SP2) and analysed by Leika Confocal Software (LCS).
Detection of surface Ig-positive clonotypic B cells by flow
cytometry using patient-individual epitope-mimicking
ligands
To detect B cells expressing clonotypic Ig on their surface,
myeloma patients’ PBMC/BMMNC, the Burkitt’s lymphoma cell
line CA46 and primary CLL cells were incubated with a 100-fold
excess of phage binding selectively to the respective patient’s or cell
line’s Ig for 10 minutes on ice. Insertless fd tet and random insert
phage YMTPPLSSQQKS were used as controls. After fixation
(Fix&Perm Kit by ADG Bio Research GmbH, Kaumberg, Austria),
Table 3. PCR-detection of clonotypic B cells in myeloma patients.*
MM patient
MM
001
MM
003
MM
008
MM
020
MM
021
MM
022
MM
023
MM
025
MM
026
MM
031
MM
032
MM
034
MM
036
MM
048
MM
050
PB 2 n.e. n.e. 2 + n.e. 2 + + + 2 + 2 + 2
BM n.e. n.e. n.e. n.e. + n.e. 2 + 2 + 2 + 2 + 2
*‘‘+’’ corresponds to detection of clonotypic IgM immunoglobulin rearrangement, ‘‘2’’ corresponds to absence of clonotypic IgM immunoglobulin rearrangement,
MM=multiple myeloma, PB =peripheral blood, BM=bone marrow, n.e. = not evaluated due to lack of material.
doi:10.1371/journal.pone.0031998.t003
Table 2. Malignant plasma cell immunoglobulin rearrangements.*
Patient
Code Isotype VH Gene VL Gene HCDR3 Sequence LCDR3 Sequence
Mutational
Status VH
Mutational
Status VL
MM001 IgG k 5-51 1-33 CVRPRIRERGPIPLDFW CQQYETFPGSF M (93.4%) M (94.6%)
MM003 IgG k 2-26 1-39 CARVSVERRRGSAFDVW CQQSYTSPRTF M (93.5%) M (90.7%)
MM008 IgG k 6-1 1-39 CARESPSGILNDYDQYYYGMDVW CLQSHSNPNTF M (90.6%) M (91.8%)
MM020 IgG k 4-39 3-20 CAGRGSNFDSDSRDFIIFDSW CQQYAASPLTF M (90.4%) M (94.3%)
MM021 IgG l 3-21 2-23 CARVQIPAALDSW CCAFGGSVTVF M (94.1%) M (93.7%)
MM022 IgG k n.e. n.e. n.e. n.e. n.e. n.e.
MM023 IgG k 5-51 4-1 CACPSRYSSVWRIDYW CQQYYYSPTWTF M (93.8%) M (95.3%)
MM025 IgG k 3-9 2-28 CVQAIRFVF CMHPVQTAPYIF M (92.7%) M (90,8%)
MM026 IgG k 3-23 3-20 CAQSNVAAAPRGWFDPW CQQYGNSPGTF M (96.5%) M (95%)
MM031 IgG l 7-4 3-23 CAREYYYNYVRYFDSW CCSYARDDTFVF M (85.4%) M (85.8%)
MM032 IgG l 2-5 3-1 CVHRRMGQLQDWYFDLW CQTWDSRTVVF M (96.2%) M (90.0%)
MM034 IgG l 1-69 1-40 CARDTDILVVDVATGFDPW CQSYDGGRSGSVVF M (88,5%) M (87,5%)
MM036 IgG k 1-f 1-5 CTRSVPSTVHNNWFDPW CQQYNNFWTF M (93,8%) M (97,5%)
MM048 IgA l 3-21 3-1 CARGGYGDNPYYHYGLDVW CQAWDSTTVVF M (92,7%) M (95.3%)
MM050 IgG k 3-15 1-5 CATEISSGASVGSVKVLW CQQYHSYLYTF M (85,4%) M (88.1%)
*MM=multiple myeloma, VH= variable heavy chain, VL = variable light chain, HCDR3 = heavy chain complementarity determining region 3, LCDR3 = light chain
complementarity determining region 3, Mutational Status = percentage of variable region germline sequence, M=mutated (.98% identity to variable region germline
sequence), n.e. = not evaluated.
doi:10.1371/journal.pone.0031998.t002
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Figure 2. Selection of specific phage-displayed peptide ligands binding to myeloma Ig. A: Enrichment of selectively binding phage on
MM021 paraprotein over three selection rounds. A X18 random peptide phage display library was screened on immobilized MM021 paraprotein.
Bound phage were recovered by K91 bacterial infection, amplified overnight, purified and subjected to the next selection round. Negative
preselection of the library was performed in selection round two and three. The selected phage were tested for binding to MM021 paraprotein and
the control human polyclonal IgG after each selection round. Bacteria transduced by recovered phage were grown on LB plates containing
tetracycline to determine the number of transducing units (TU) by colony counting. Ig = immunoglobulin, MM=Multiple Myeloma. B: Phage selected
on myeloma Ig specifically bind the antibody on which they were selected. Examplarily, binding of paraprotein MM021-selected phage
FLNGCDKEDWMCWVTT and control phage fd tet to MM021 monoclonal antibody, MM021 paraprotein and control human IgG is shown. Bound
phage were quantified by Enzyme-linked Immunosorbent Assay (ELISA). Data are shown as means from triplicate experiments (6 SEM). C: The
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cell-bound phage were detected with an anti-fd bacteriophage
biotin-conjugated antibody (Sigma, Saint Louis, Missouri) followed
by fluorescent labeling with streptavidin-FITC (Invitrogen, Camar-
illo, California). B cells were stained with a CD19 allophycocyanin-
conjugated antibody (CD19-APC, Abcam, Cambridge, UK). To
exclude unspecific binding, stainings were also performed on
healthy donor PBMC. To establish the sensitivity level of this
protocol, spiking experiments with stained and unstained CA46 and
primary CLL024 cells were conducted. All measurements were
taken on a FACSCalibur flow cytometer (BD, Heidelberg,
Germany) and analyzed with the FlowJo software (Treestar).
Results
Detection of IgM-positive clonotypic B cells by PCR
15 myeloma patients with different clinical features were included
in this study (Table 1). The variable heavy (VH) and variable light
(VL) chain Ig rearrangement of the malignant PC clone was
amplified using family- and isotype-specific primer pairs (Table S1)
and sequenced as described in the Methods section. Table 2 lists the
myeloma patients’ Ig isotype, VH and VL gene usage and
complementarity determining region 3 sequences (HCDR3 and
LCDR3) as well as the mutational status of the VH and VL chain.
PCR-based approaches to detect clonotypic B cells may be
prone to different kinds of errors as described in the introduction
section and may therefore not be able to predict the presence or
absence as well as the frequency of these potential myeloma
precursor cells. However, in an attempt to compare our patient
cohort to the cohorts of other studies, we used a PCR protocol
similar to what was used by other investigators to screen PBMC
and BMMNC for Ig-positive clonotypic B cells. As previously
published work most commonly analyzed IgM-isotype expressing
clonotypic cells, a semi-nested PCR approach with HCDR3- and
IgM-specific primers was established as illustrated in Figure 1A.
Figure 1B shows semi-nested PCR reactions for three exemplary
myeloma patients. Whereas patient MM021 and MM025 had
clear evidence of clonotypic B cells in peripheral blood and bone
marrow (Figure 1B, upper and middle panel), in patient MM036
no specific PCR products could be amplified, suggesting the
absence of clonotypic B cells in peripheral blood and bone marrow
of this patient (Figure 1B, bottom panel). Of all evaluable patients,
50% exhibited clonotypic cells in the peripheral blood as
evidenced by PCR (Table 3). This frequency is in line with data
from the literature indicating that 40%–87% of myeloma patients
show evidence of clonotypic B cells in the peripheral blood by
PCR [15,17,18]. In .80% of PCR-positive patients, clonotypic B
cells could also be detected in bone marrow (Table 3). However, in
this cellular compartment PCR signals were generally weaker,
potentially corresponding to the reduced relative frequency of B
cells in bone marrow as compared to peripheral blood.
Selection of patient-individual ligands specifically
binding to myeloma Ig
After having identified patients with PCR-based evidence of
clonotypic B cells in the blood and/or bone marrow, we set out to
establish a method allowing us to physically label clonotypic cells
in an attempt to precisely quantify and eventually characterize this
interesting cellular compartment. We chose the patient-individual
clonotypic Ig as cellular target for the development of specific
ligands mimicking the epitope recognized by this immunoglobulin.
This choice was based on two major reasons: First, clonotypic Ig
with its highly patient-individual and tumor-specific paratope
region is the most reliable clonal marker of this B cell population.
Second, clonotypic Ig is expressed on the surface of B cells,
rendering it accessible to our labeling strategy.
We used combinatorial phage display peptide library screenings
selecting epitope-mimicking ligands which specifically bind to
myeloma Ig. Peptides were selected on all myeloma Igs,
irrespective of PCR-based evidence for clonotypic B cells. For
the first phage library selections, myeloma Ig was recombinantly
expressed as IgG-Fab in a prokaryotic system (selections on
MM001, MM003, MM008 and MM020). As this recombinant
approach is very labor-intensive, we also evaluated naturally
occurring IgG or IgA paraproteins purified from serum as a source
of target Ig. Paraproteins were purified by protein-A (IgG) or
jacalin (IgA) chromatography and purity was assessed by
coomassie staining of electrophoretically separated eluted Ig
fractions (data not shown). Given that all patients had highly
elevated Ig serum levels at the time of sample collection,
contamination by non-paraprotein IgG or IgA was deemed
negligible. Indeed, in most of the cases, binding phage could be
enriched over three to four selection rounds on recombinantly
expressed Fab as well as on purified paraprotein (exemplarily
shown in Figure 2A) with at least one out of four random peptide
phage libraries with different insert design (X7, X12, X18 and
X4CX6CX4= beta-sheet conformation [BS]). In only three out of
15 myeloma cases selections did not yield binding phage,
potentially indicating that none of our peptide designs mimics
the natural epitope of these antibodies. Table 4 lists the myeloma
Igs and the peptide sequences selected thereon. All of the selected
phage, but not random insert control phage, bound specifically to
the myeloma Ig on which they were selected and not to control
Igs, exemplarily shown in Figure 2B for MM021-selected phage
FLNGCDKEDWMCWVTT binding to MM021 paraprotein.
Phage FLNGCDKEDWMCWVTT, selected on the paraprotein
of patient MM021, also bound to recombinantly expressed
MM021 monoclonal antibody, providing proof of concept that
selections on purified paraprotein yield phage clones selectively
binding to the clonotypic Ig and not to potentially contaminating
normal serum Ig (Figure 2B). The higher binding level of this
phage to MM021 monoclonal antibody probably reflects the
higher degree of purity as compared to MM021 paraprotein.
Likewise, phage selected on recombinantly expressed antibodies
bound specifically to the respective patient’s native paraprotein
verifying correct folding of the recombinant antibody used as
target for phage selections (data not shown). To confirm that the
selected phage displayed peptides bind the respective myeloma Ig
independently of other phage components, we exemplarily
performed competition assays with a GST-fusion protein contain-
ing the phage-derived peptide FLNGCDKEDWMCWVTT
protein GST-FLNGCDKEDWMCWVTT blocks binding of phage FLNGCDKEDWMCWVTT to MM021 paraprotein. MM021-selected phage
FLNGCDKEDWMCWVTT was incubated on MM021 paraprotein in the presence of increasing amounts of GST-FLNGCDKEDWMCWVTT or GST alone.
Bound phage were quantified as in B. Data are shown as relative values compared to binding of a control phage (means from triplicate experiments
6 SEM). GST = glutathione S-transferase. D: Phage selected on myeloma Ig specifically bind their target and do not cross-react with other Igs. Binding
of phage clones selected on the myeloma Ig of patients MM021, MM034 and MM036 as well as random control phage YMTPPLSSQQKS and fd tet to
different myeloma paraproteins and recombinantly expressed Fab fragments (MM001, MM003, MM008, MM020) as well as control polyclonal IgG and
Bovine Serum Albumin is shown. Bound phage were quantified as numbers of transducing units (TU) based on bacterial infection (means from
triplicate platings 6 SEM).
doi:10.1371/journal.pone.0031998.g002
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Table 4. Phage displayed peptide sequences binding to myeloma immunoglobulins.*
MM Lib. X7 Lib. X12 Lib. X18 Lib. BS
001{ YPNYEKWSRWPF GLPIASPEKYTFWPWKLW
SNMTLKELMWPF TFVGAYRTQWLEQGRFPH
003{ VWYAWMEDLDHAPEFWKI
008{ RTPIPKPAWSWRSLAYNS
PQDFYRSRFWDAHWMYWQ
PRDYRSLLYGFHDLTTKV
020{ YKTPYHMWQEWV WYYPDEEAYENFYELWSR
AQHNFIETSYDMFQQFRF
021{ DRDIYQLSNLVEYLA FLNGCDKEDWMCWVTT
GSGYSSNNLVAQKPKATL
022{ TDPWSKS WHICLDERAMCQIKELRV KSYGCKEERAHCYGQV
WAPFSLL QDQYTDCSIKGEHTMVCG IRMQCREERSSCSMIS
GTWVCRDERATCRSAS
SKVVCYDERCTCGRNA
MSGRCLEHRATCYPWN
023{ VIGPSSL TQARLDWVNDEYAPSLR PELRCLEWIHICYAIG
YFSPSFH GILLRSFQEFWLNEEYMY GRNICLLGDHQCAQVN
RWENDEFWGMISLKEAML
YRWLMRVGIQDRHHQEMG
025{ PDLSSQRYIIEGSGQKPQ SLSPCQVWDAGCQSAG
PILQYPLVTGTGTKEGIH REEVCMETVPICDLYF
PLGQSGRDKAESKTKGWT GKHLCRPWGLACVAMQ
PKILSGAGNKVEGASHGA
GRAGEKMISGDGNKIHES
RDQGYRAPYHVGLGARSG
026{ PEQYCCRSRWSCQICH
SREVVWWDGLSLVRSR
LLTPCVTRWGNCMQGL
TPSHCPSIRARCQATI
HPYLCAMRSDRCAMTV
AQFLCSDLGRVCTRVS
031{ SEAIQKNSGNEQ
FGQQKTSGNEEG
NGLLHQKNAGNE
ALHKTSGNEMDI
AGHPKDSGNEWA
034{ ADSSKRCNFNQC
YNGTPSTVHLLP
036{ EPYTPHLGQALW
IXXRGLPTDMXG
GFESSGKYLRKQ
VDFPNAWKWWTE
SSAGPEQPRLMW
YPELPRWFPPNY
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which inhibited binding of phage FLNGCDKEDWMCWVTT to
MM021 paraprotein in a concentration-dependent manner
(Figure 2C). To evaluate our phage clones for cross-reactivity with
different myeloma Igs, we performed extensive binding assays as
shown for three exemplary phage clones selected on MM021,
MM034 andMM036 as well as respective control phage (Figure 2D).
These assays suggest that phage clones selected on myeloma Ig bind
their respective target in a highly specific manner and do not cross-
react with other myeloma Igs or unrelated proteins.
Immunofluorescence imaging of surface Ig-positive
clonotypic myeloma B cells
Next, we developed an immunofluorescence protocol allowing
us to stain clonotypic myeloma B cells from peripheral blood and
bone marrow. As such cells do certainly not represent the bulk of
PBMCs or BMMNCs, but constitute only a B cell fraction of
unknown size, we had to establish our staining protocol using
purely monoclonal B cell systems as positive controls. We therefore
chose the Burkitt’s lymphoma cell line CA46 and primary CLL
cells from patient 024 (CLL024), both expressing an individual
monoclonal surface IgM. As Ig surface density on clonotypic B
cells is unknown so far, these two models seemed particularly
suited: Whereas the Burkitt’s lymphoma cell line represents a
model with high Ig surface density, the CLL model is
characterized by extremely low Ig surface expression. The CLL
patient’s as well as the Burkitt’s lymphoma’s Ig were recombi-
nantly produced as IgG1 antibodies. Phage displayed peptide
ligands were selected targeting the paratope region of the
respective monoclonal Igs and subjected to specificity testings as
described for the selections on myeloma Igs (Ref. [42] and data not
shown). Cells were loaded with the respective selectively binding
phage (phage-CA46 for CA46 and phage-CLL024 for CLL024) or
control phage, washed, sedimented on slides and cell-bound phage
were detected by FITC-labeling. Confocal microscopic imaging
revealed bright and specific membrane staining for both cellular
systems (green ‘‘corona’’ in Figure 3A and B). CA46 cells stained
with phage-CLL024, CLL024 cells stained with phage-CA46 and
the control burkitt’s lymphoma cell line DG-75 stained with both
phage did not show a FITC-signal (data not shown). These
findings served as proof-of-principle that phage selected on
patient- and clone-specific IgG can be used to specifically label
the clonotypic surface IgM on parental cells. In a next step, we
stained myeloma PBMCs with the respective phage clones and
control phage to screen the samples for clonotypic B cells. As
expected, none of the myeloma samples without PCR-detectable
clonotypic B cells showed any phage-positive cells by immunoflu-
orescence imaging (data not shown). Surprisingly, however,
even most of the PCR-positive samples showed no evidence of
specifically phage-labeled cells (exemplarily shown for MM031
in Figure 3C). These findings suggested that only a very slim
percentage of myeloma PBMCs can be considered to express the
clonotypic Ig rearrangement of the malignant PC clone. Only
PBMCs from patient MM021 showed sparse specifically labeled
cells (Figure 3D, white arrows) when stained with the Ig-specific
phage FLNGCDKEDWMCWVTT, whereas the control phage fd
tet did not show any staining. To exclude unspecific binding of
phage FLNGCDKEDWMCWVTT, unrelated PBMCs of healthy
donors were stained with this phage yielding no specific signals (data
not shown). However, as this technique does not allow to exactly
determine the frequency of such cells, this data was complemented
by precise flow cytometric quantification.
Flow cytometry-based detection and quantification of
surface Ig-positive clonotypic myeloma B cells
As for the immunofluorescence experiments, CA46 and
CLL024 cells were used as positive controls to establish an
appropriate flow cytometric protocol to screen the blood and bone
marrow of myeloma patients for clonotypic B cells. The two-color
flow cytometry staining protocol could be adopted from the
immunofluorescence experiments with minor modifications. Cell-
bound phage were stained with fluoresceinisothiocyanate-conju-
gated secondary detection (denominated as ‘‘phage-FITC’’), B
cells were stained with a CD19 allophycocyanin-conjugated
antibody (‘‘CD19-APC’’). Under these conditions, CA46 and
CLL024 cells stained FITC-positive when loaded with their
respective specific phage clones (phage-CA46 for CA46 and
phage-CLL024 for CLL024) whereas the respective control
phage did not show any staining (Figure 4A and B, first two
panels). CA46 cells stained with phage-CLL024 and CLL024
cells stained with phage-CA46 did not show a FITC-signal (data
not shown). To determine the sensitivity level of this flow
cytometry protocol, control phage-stained CA46 cells were then
spiked with decreasing amounts of CA46 cells stained with the
specifically binding phage-CA46 in a 5%, 2.5%, 1%, 0.5%, 0.1%,
0.05% and 0.005% ratio (Figure 4A). The same spiking ex-
periment was carried out for CLL024 with the specifically
binding phage-CLL024 (Figure 4B). In both spiking experiments
stained cells could be clearly and repeatedly detected down to
ratios of 0.1–0.05%, corresponding to a sensitivity level of this
flow cytometry protocol of around 1023.
In further experiments, PBMCs and BMMNCs of myeloma
patients as well as healthy donor control PBMCs were stained with
specific and control phage for detection of clonotypic B cells in the
myeloma samples. All phage used in these experiments were
initially tested for unspecific B cell binding on healthy donor
control PBMCs and on a number of unrelated myeloma PBMCs.
None of the phage clones showed preferential binding as
compared to control phage under these control conditions (data
MM Lib. X7 Lib. X12 Lib. X18 Lib. BS
VPQLPRYYSVSS
QIPGWLRTGLEA
*Libraries with 7-mer linear (X7), 12-mer linear (X12), 18-mer linear (X18), and 14-mer constrained beta sheet (BS) inserts were selected on myeloma Ig of patients
MM001–MM036. The table lists the peptide insert sequences (single letter amino acid code) of phage clones for which specific binding to the respective Fab fragment
and/or paraprotein was validated in single clone binding assays.
{phage selection on monoclonal Fab fragment.
{phage selection on paraprotein.
doi:10.1371/journal.pone.0031998.t004
Table 4. Cont.
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not shown). The first two rows of Figure 4C show representative
flow cytometric plots of patients MM031 and MM034 after B cell
gating. Like these two exemplary patients, most other patients’
PBMCs and all BMMNCs were negative for clonotypic B cells by
flow cytometry. This further corroborates the immunofluorescence
imaging data, indicating that the absolute number as well as the
relative percentage of clonotypic B cells may be very low in the
majority of myeloma patients. Based on the previously established
sensitivity level of this assay, the frequency of clonotypic B cells is
less than one clonotypic B cell per 1000 PBMCs in most myeloma
patients. Only PBMCs of patient MM021 exhibited detectable
amounts of clonotypic B cells by flow cytometry in line with the
immunofluorescence data described above (Figure 4C, bottom
row). These cells accounted for about 0.15% of PBMCs and 5% of
B cells in this patient. In view of the capacity of our assay to detect
even minute fractions of idiotype expressing cells by the epitope-
mimicking phage, these data show that the actual number of
clonotypic cells is exceedingly low (presumably below the assay’s
detection limit of 1023 cells in the majority of samples, even if
PCR suggests their presence).
Discussion
Clonotypic B cells and their biological significance in multiple
myeloma are controversially discussed. While many groups have
reproducibly identified Ig-positive B cells expressing the same
clonal Ig rearrangement as the malignant PC in about 40–87% of
myeloma patients, their proportion relative to normal PBMCs and
their potential role in the initiation, relapse and progression of
multiple myeloma remains largely unclear [15,17,18]. A major
limitation to solve this controvery has been the impossibility to
morphologically identify or directly isolate these clonotypic cells
for further functional analyses to determine their biological role.
Here, we present a technique to phenotypically detect, quantify
and isolate clonotypic myeloma B cells by flow cytometry by
means of epitope-mimicking ligands highly specific for binding to
myeloma-idiotypic surface immunoglobulin, independently of Ig
isotype. Our cohort comprised 15 patients with confirmed
multiple myeloma at different disease stages. Fifty percent of
informative patients showed evidence of clonotypic B cells in
peripheral blood and/or bone marrow by semi-nested PCR using
HCDR3-specific patient-individual primers, in line with pub-
lished data. Surprisingly, in most patients with PCR-positivity for
clonotypic B cells, the number and relative proportion of such
cells was below the sensitivity level of our flow cytometry
protocol. This sensitivity level had precisely been determined by
spiking experiments using two different monoclonal B cell systems
with different Ig receptor density (Burkitt’s lymphoma CA46 and
CLL024) to reliably range around 1023. This indicates that in the
majority of myeloma patients, less than one out of 1000 PBMCs
or BMMNCs corresponds to a clonotypic B cell. Only one patient
of our cohort had detectable amounts of clonotypic B cells by
flow cytometry and immunofluorescence imaging, accounting for
about 0.15% of PBMCs and 5% of B cells. These findings clearly
contradict the estimates of 0.24%–25% of PBMCs and up to two
thirds of B cells suggested to be clonotypic B cells by previously
published limited dilution PCR assays [15,16,17]. Although for
the time being there is no definitive explanation for this
unexpected discrepancy, the qualitative detection of clonotypic
B cells by semi-nested PCR could be flawed for example by
unspecific annealing of the CDR3-primer. Such unspecific
annealing may seem implausible at first glance as this
immunoglobulin region represents the most variable part of the
antibody. However, the diversity in this region is created in part
by reading frame shifts, which result in different amino acid
sequences, whereas the DNA sequence can be similar or even
identical in different antibody clones. This would allow for primer
annealing in antibody clones with different CDR3 amino acid
sequences giving rise to false positive PCR results and potentially
to an overestimation of the frequency of clonotypic B cells by
PCR-based approaches.
From the first description of clonotypic B cell Ig rearrange-
ments in 1993 (Ref. [11]) until today, there has been much debate
about the biological significance of clonotypic B cells in myeloma
as outlined in the introduction section of this manuscript. Animal
models ascribing proliferative potential exclusively to clonotypic
B cells and the estimated frequency of such cells in remission and
relapse have supported the hypothesis that clonotypic B cells may
continuously replenish the tumor compartment as ‘‘feeder’’ cells
[14,15,16,22,23,24,26,27,28,29]. On the other hand, alternative
animal models and recent genetic analyzes of clonal hierarchies
as well as class switch recombination events in the B cell lineage
of multiple myeloma patients challenge the myeloma stem cell
hypothesis [30,31,33,35,37,38,39]. The prominent role assumed
by clonotypic B cells over the past years of myeloma research has
probably – amongst other factors – to do with the surprisingly
high percentages of such cells found by PCR-based quantifica-
tion. If clonotypic B cells on average constituted about two thirds
of all B cells in myeloma patients and if they remained constant
or even increased over the course of the disease, they would have
to have a survival advantage compared to normal B cells. Either
this survival advantage would reflect a (pre-) malignant state of
such B cells or – although less likely – clonotypic B cell survival
and proliferation would have to be driven by some external
signal, e.g. a persisting, non-eliminated antigen that had selected
the B cell clone in the first place. Both hypotheses, particularly
the first one, would be highly compatible with a ‘‘feeder’’ function
of clonotypic B cells. On the other hand, much lower levels of
clonotypic B cells, as suggested by our study, do not necessarily
contradict these hypotheses and especially do not exclude a
causal role of these cells as progenitor cells in disease progression.
It should be pointed out, however, that only a limited percentage
Figure 3. Detection of surface Ig-positive clonotypic B cells by immunofluorescence using patient-individual ligands. A and B: Ig-
selected phage bind to surface Ig-positive parental B cells as visualized by immunofluorescence. As proof of principal an immunofluorescence
staining protocol was set up using two different monoclonal B cell systems as positive controls as described in the Methods and Results sections.
Phage-CA46 selected on the Ig of the Burkitt lymphoma cell line CA46 (panel A, upper row) as well as control phage (panel A, bottom row) were used
to stain CA46 cells. Phage-CLL024 selected on the Ig of CLL patient 024 (panel B, upper row) as well as control phage (panel B, bottom row) were
used to stain primary CLL024 cells. Phage were visualized by immunofluorescence (FITC; green). Nuclei were stained with DAPI (blue). Images are
shown at low (right panel) and high magnification (left panel). Images were obtained by confocal microscopy (Leika TCS SP2 AOBS; lens 636) and
analyzed using the Leika confocal software. CLL = chronic lymphocytic leukemia. C: Staining of MM031 PBMCs with MM031 Ig-selected phage
AGHPKDSGNEWA and control phage to detect potential surface Ig-positive clonotypic B cells. Staining and imaging was performed as in A and B.
PBMC=peripheral blood mononuclear cell. D: Staining of MM021 PBMCs with MM021 Ig-selected phage FLNGCDKEDWMCWVTT and control phage
to detect potential surface Ig-positive clonotypic B cells. Staining and imaging was performed as in A and B. The white arrows point to single surface
Ig-positive clonotypic B cells from patient MM021.
doi:10.1371/journal.pone.0031998.g003
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of myeloma patients do have PCR-based evidence of B cells
clonally related to the malignant plasma cell clone (50% in our
study) and even in PCR-positive patients, clonotypic B cells seem
to be a very rare event according to our data. Therefore, it seems
rather implausible that a clonotypic B cell compartment is an
indispensable ‘‘feeder’’ of the malignant PC compartment and an
essential prerequisite of myeloma maintenance and progression.
Given the apparent rarity of clonotypic B cells in myeloma, it is
conceivable that these cells are non-malignant remnants, which
may have initially given rise to the malignant plasma cell clone,
but which do not have any significance in tumor maintenance.
Taking into account the long term persistence of such B cell
clones over the course of the disease, they may in fact resemble
long-lived memory B cells with some sort of self-renewing
properties.
Detection of clonotypic B cells in this study as well as in
others has been limited so far to the peripheral blood and bone
marrow. This choice has certainly not been made merely for
scientific interest, but primarily because these cellular compart-
ments are easily accessible in myeloma patients. However, to get
a more comprehensive picture about clonotypic B cells in
multiple myeloma, it may be of interest to study other lymphatic
tissues, such as spleen or lymph nodes to exclude that these
organs possibly serve as niches harboring clonotypic B cells. Our
established flow cytometry protocol may serve as a tool to
quantitate clonogenic B cells also from different lymphoid
organs.
Taken together, this is the first report on phenotypic detection
and quantification of clonotypic myeloma B cells using highly
patient- and clone-specific ligands as tracers for this rare B cell
population. Our new approach not only serves to precisely
quantify this B cell population in a complementary way to previous
quantification attempts. More importantly, by phenotypic detec-
tion and isolation of pure populations of clonotypic B cells, it may
pave the way to experimentally address some of the apparent
inconsistencies and controversies regarding the clinical role of
clonotypic B cells in multiple myeloma in the future.
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